Manabu Tamura, Sayaka Tomihara, Shinichiro Okazaki, Hiroki Yokote, Masahiro Uemura and Kazumi Nishikawa
In patients with Alzheimer’s disease (AD) who don't have surgical indications, anti-AD therapy is sometimes administered, while there are only four more or less effective drugs available. Of note, currently no medication exists, which might cure AD and everyone therapeutics may only slow the disease progression. Considering that, needless to say, the amount of AD patients will increase, gradually making it tougher for doctors to manage all cases of dementia, which can require modification of the healthcare system generally. It is particularly important in Japan, with a now rapidly aging society; the govt should clearly recognize possible increase within the incidence of dementia. Currently, there are a range of neuroimaging initiatives for AD worldwide (ADNI, CATI, etc.), and a number of other clinical trials are initiated (EPAD consortium, A4, GAP foundation, Memento, etc.). Japan thus needs international collaboration with medical practitioners and scientists from other countries. On the opposite hand, it's important to make AD platform in an exceedingly way of recent and innovative public-private partnership (PPP). This AD platform should aim at dementia research because the main target (e.g., risk reduction, prevention, early diagnosis, treatment, and life support), and also to ascertain common paradigm directed at development of the registry, investigated patients cohort, and bio-bank. Collaboration of personal enterprises, academia and public entities (e.g., basic science in MEXT, clinical application in MLHW, integration of various fields in METI) may have a right away impact on the event of dementia research. Additionally, Japan may further accelerate AD studies at a brand new system for medical research and development (Japan Agency for Medical Research and Development–AMED), which has extended its activities and currently grips project and budget management (e.g., new orange plan in MLHW). There aren't any doubts that fair evaluation of clinical leads to AD considering COI (conflict of interests) should be done.
